Skip to main content
ABOS logo

ABOS · Acumen Pharmaceuticals, Inc. · Earnings Calls, Transcripts & Webcasts

Track ABOS — free
$0.19 -0.01 (-3.52%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$13.49M
Shares
72.33M
Volume · Nov 20 2.71M Avg daily vol (3M) 2.7M

Acumen Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Acumen Pharmaceuticals, Inc. (ABOS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-10-26
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2026 Earnings Call Transcript
Confident tone Phase III and subcutaneous strategy Clinical trial execution Safety and biomarkers
Net income
−$25.37M
Diluted EPS
$-0.35
Audio Transcript Slides 8-K10-Q
Capital Markets Day
Investor event
2026-09-16
Acumen Pharmaceuticals, Inc. (ABOS) September 16, 2026 Capital Markets Day Transcript
No reported result — non-financial event
Audio Transcript Slides
Capital Markets Day
Investor event
2026-09-16
Acumen Pharmaceuticals, Inc. (ABOS) September 16, 2026 Capital Markets Day Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-10
Acumen Pharmaceuticals, Inc. (ABOS) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-12
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
Confident tone Top-line ALTA-2/altitude readout expectations Mechanism and target (oligomers vs plaque) Sobbernatug (SabernaTug) safety/tolerability differentiation
Net income
−$32.72M
Diluted EPS
$-0.45
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-05-14
Acumen Pharmaceuticals, Inc. (ABOS) May 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-12
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Confident tone EBD / JCR Pharmaceuticals partnership IgG2 safety differentiation vs IgG1 antibodies Altitude AD Phase II readout
Net income
−$20.74M
Diluted EPS
$-0.33
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
Confident tone EBD program with JCR Altitude AD Phase II readout AD field sentiment and unmet need
Net income
−$25.14M*
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript
Positive tone ACU234 Next-Generation Antibody EBD Program with JCR Pharmaceuticals Competitive Landscape / GLP-1 Readouts
Net income
−$26.45M
Diluted EPS
$-0.44
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript
Positive tone JCR Pharmaceuticals partnership (EBD program) ARIA safety profile Strategic portfolio expansion
Net income
−$40.95M
Diluted EPS
$-0.68
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
Confident tone Phase 2 ALTITUDE-AD enrollment completion and timeline Sabirnetug clinical profile and differentiation Biomarkers as treatment monitoring tools
Net income
−$28.80M
Diluted EPS
$-0.48
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call
Net income
−$37.15M*
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
Confident tone Sabirnetug clinical development ARIA safety profile Enrollment progress and site activation
Net income
−$29.77M
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript
Confident tone ALTITUDE-AD Phase 2 enrollment and execution Biomarker strategy (pTau217, synaptic markers) Competitive landscape and field validation
Net income
−$20.54M
Diluted EPS
$-0.34
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
Confident tone Sabirnetug Clinical Profile and Differentiation Subcutaneous Formulation ALTITUDE-AD Phase II Trial
Net income
−$14.87M
Diluted EPS
$-0.25
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-26
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript
Confident tone Phase 1 INTERCEPT-AD results Sabirnetug (ACU193) drug profile Phase 2 ALTITUDE-AD study
Net income
−$16.50M*
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2023 Earnings Call Transcript
Net income
−$12.96M
Diluted EPS
$-0.24
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2023 Earnings Call Transcript
Net income
−$11.61M
Diluted EPS
$-0.28
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2023 Earnings Call Transcript
Net income
−$11.31M
Diluted EPS
$-0.28
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-27
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2022 Earnings Call Transcript
Net income
−$12.87M*
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2022 Earnings Call Transcript
Net income
−$10.71M
Diluted EPS
$-0.26
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Transcript
Net income
−$10.15M
Diluted EPS
$-0.25
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Call Transcript
Net income
−$9.13M
Diluted EPS
$-0.23
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-28
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Transcript
Net income
−$8.35M*
Audio Transcript Slides 8-K10-K
Showing 1–24 of 24 webcasts
Key facts CIK 1576885 CUSIP 00509G209 13F (30d) 103 filings 89 filers Visit website Investor relations